These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 22753230)

  • 1. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
    McBride SM; Perez DA; Polley MY; Vandenberg SR; Smith JS; Zheng S; Lamborn KR; Wiencke JK; Chang SM; Prados MD; Berger MS; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2010 Mar; 97(1):33-40. PubMed ID: 19705067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
    Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
    Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
    Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.
    Wiencke JK; Zheng S; Jelluma N; Tihan T; Vandenberg S; Tamgüney T; Baumber R; Parsons R; Lamborn KR; Berger MS; Wrensch MR; Haas-Kogan DA; Stokoe D
    Neuro Oncol; 2007 Jul; 9(3):271-9. PubMed ID: 17504928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.
    Peterziel H; Müller J; Danner A; Barbus S; Liu HK; Radlwimmer B; Pietsch T; Lichter P; Schütz G; Hess J; Angel P
    Neuro Oncol; 2012 Apr; 14(4):426-39. PubMed ID: 22394497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction molecules in gliomas of all grades.
    Ermoian RP; Kaprealian T; Lamborn KR; Yang X; Jelluma N; Arvold ND; Zeidman R; Berger MS; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2009 Jan; 91(1):19-26. PubMed ID: 18759130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-17 targets PTEN and facilitates glial scar formation after spinal cord injuries via the PI3K/Akt/mTOR pathway.
    Luan Y; Chen M; Zhou L
    Brain Res Bull; 2017 Jan; 128():68-75. PubMed ID: 27693649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
    Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
    BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
    Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
    BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Mohamed E; Kumar A; Zhang Y; Wang AS; Chen K; Lim Y; Shai A; Taylor JW; Clarke J; Hilz S; Berger MS; Solomon DA; Costello JF; Molinaro AM; Phillips JJ
    Neuro Oncol; 2022 Sep; 24(9):1471-1481. PubMed ID: 35287169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
    Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
    Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGI3 Suppresses Glioma Cell Proliferation via Upregulation of PTEN Expression.
    Ma Q; Zhang Y; Meng R; Xie KM; Xiong Y; Lin S; He ZL; Tao T; Yang Y; Zhao JZ; He JQ
    Biomed Environ Sci; 2015 Jul; 28(7):502-9. PubMed ID: 26248734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.
    Waldron JS; Yang I; Han S; Tihan T; Sughrue ME; Mills SA; Pieper RO; Parsa AT
    J Clin Neurosci; 2010 Dec; 17(12):1543-7. PubMed ID: 20822910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma.
    Beccari S; Mohamed E; Voong V; Hilz S; Lafontaine M; Shai A; Lim Y; Martinez J; Switzman B; Yu RL; Lupo JM; Chang EF; Hervey-Jumper SL; Berger MS; Costello JF; Phillips JJ
    Mod Pathol; 2024 Jun; 37(6):100488. PubMed ID: 38588881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.